77 results
Page 4 of 4
8-K
EX-99.1
g3eo6z0z1yr0 ml
29 Oct 20
Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
7:06am
8-K
EX-99.1
ml53qqm7twuf43466y
9 Oct 20
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
5:20pm
S-8
EX-5.1
w2bdaj 95
29 Jul 20
Registration of securities for employees
5:09pm
S-8 POS
EX-5.1
2n0mv296
29 Jul 20
Registration of securities for employees (post-effective amendment)
4:51pm
S-8 POS
EX-5.1
px2fbg
29 Jul 20
Registration of securities for employees (post-effective amendment)
4:41pm
S-8 POS
EX-5.1
ptzz2l
29 Jul 20
Registration of securities for employees (post-effective amendment)
4:35pm
S-8 POS
EX-5.1
1exovx4a 2042v31d9m6
29 Jul 20
Registration of securities for employees (post-effective amendment)
4:30pm
S-8 POS
EX-5.1
aeqi032j678
29 Jul 20
Registration of securities for employees (post-effective amendment)
4:23pm
8-K
EX-99.1
5un5358pi2sd 489lm
29 Jul 20
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
7:08am
8-K
EX-99.2
h59wlot9lc6ax4 tvo5d
29 Jul 20
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial Expectations
7:08am
8-K
EX-99.1
g0ssiu
29 Apr 20
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
7:05am
8-K
3iwbs
29 Apr 20
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
7:05am
8-K
EX-99.2
58jjgb7rez katu
29 Apr 20
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
7:05am